CEL-SCI Corporation (NYSE American: CVM) announced the closing of its best-efforts public offering of 6 million shares of common stock at $1.20 per share, generating gross proceeds of approximately $7.2 million before fees and expenses. The company stated that net proceeds will be used to support continued development of Multikine, its investigational immunotherapy for head and neck cancer, as well as for general corporate purposes and working capital. This capital infusion comes at a critical time as CEL-SCI advances its clinical pipeline and seeks to bring Multikine closer to potential regulatory approval.
Multikine (Leukocyte Interleukin, Injection) is designed to boost the immune system before surgery, radiotherapy, and chemotherapy have damaged it, thereby maximizing the potential impact on patient survival. The therapy is administered after diagnosis but before surgical intervention, aiming to help the immune system target the tumor while it is still relatively intact. Multikine has been dosed in over 740 patients and has received Orphan Drug designation from the U.S. Food and Drug Administration for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck. This designation provides certain development and commercial incentives, including tax credits and market exclusivity upon approval.
The completion of this offering strengthens CEL-SCI's financial position as it continues to navigate the complex regulatory landscape. The company operates facilities in Vienna, Virginia, and near Baltimore, Maryland, and is focused on developing innovative immunotherapies for cancer. For more details on the offering, the full press release is available at https://ibn.fm/T5Ng2.
Investors and stakeholders will be watching closely as CEL-SCI deploys these funds to advance Multikine's clinical trials and potentially move toward a Biologics License Application submission. The company's approach of intervening immunologically before standard treatments could represent a paradigm shift in head and neck cancer therapy, offering hope for improved outcomes. Additional information about CEL-SCI and its pipeline can be found at https://cel-sci.com/.
